Differences in clinical features between axial psoriatic arthritis and axial spondyloarthritis: a systematic review and meta-analysis of observational studies - Scorecard - MDSpire
Advertisement
Differences in clinical features between axial psoriatic arthritis and axial spondyloarthritis: a systematic review and meta-analysis of observational studies
Clinical Scorecard: Comparative Analysis of Clinical Characteristics in Axial Psoriatic Arthritis and Axial Spondyloarthritis: A Systematic Review and Meta-Analysis of Observational Research
At a Glance
Category
Detail
Condition
Axial Psoriatic Arthritis and Axial Spondyloarthritis
Key Mechanisms
HLA-B27 positivity and IL-23/IL-17 axis activation
Target Population
Patients with axial involvement in Psoriatic Arthritis and Axial Spondyloarthritis
Care Setting
Observational studies and clinical trials
Key Highlights
No significant differences in disease activity scores between ax-PsA and ax-SpA.
ax-PsA associated with lower HLA-B27 positivity compared to ax-SpA.
Subgroup analyses show ax-PsA has modestly better BASFI scores than ax-SpA.
IL-23 inhibitors may improve axial symptoms in ax-PsA patients.
Clinical differentiation should include HLA-B27 testing and imaging.
Guideline-Based Recommendations
Diagnosis
Incorporate HLA-B27 testing for clinical differentiation.
Management
Consider IL-23 inhibitors for improving axial symptoms in ax-PsA.
Monitoring & Follow-up
Evaluate disease activity scores and imaging findings.
Risks
Limited efficacy of biologics targeting downstream inflammatory cytokines in ax-SpA.
Patient & Prescribing Data
Patients with axial Psoriatic Arthritis and Axial Spondyloarthritis.
IL-23 inhibitors may be more effective for ax-PsA than for ax-SpA.
Clinical Best Practices
Utilize standardized diagnostic criteria where available.
Conduct thorough assessments of disease activity and functional outcomes.
Consider regional variations in HLA-B27 positivity in clinical evaluations.
